[Botulinum toxin A in the treatment of morbid obesity]

Cuadros Celorrio M, Llanos Mendez A
Record ID 32011001544
Authors' objectives: Treatment of obesity is based on four pillars: dietary, pharmacological and surgical treatment, and changes in lifestyle. In recent years the use of pharmacological agents capable of inhibiting gastric motility has been suggested. Botulinum toxin type A is an inhibitor of acetylcholinemediatedperistalsis, which is the main agent for gastric motility. The specifi c objectives of this report are focused on determining the effectiveness and safety of administering botulinum toxin type A in the treatment of morbid obesity. Two randomized trials of mild-high methodological quality were identifi ed that compared treatment with botulinum toxin A with a placebo. One of the trials demonstrated a statistically signifi cant decrease in body weight in the group treated with botulinum toxin A. The group treated with botulinum toxin A lost 11.8 kg vs. 5.5 kg lost by those receiving saline (p <0.0002). Endoscopic administration of botulinum toxin A did not cause any adverse effects due to the procedure or the substance administered.
Project Status: Completed
Year Published: 2011
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Spain
MeSH Terms
  • Obesity, Morbid
Organisation Name: Andalusian Health Technology Assessment Area
Contact Address: Area de Evaluacion de Tecnologias Sanitarias Sanitarias de Andalucia (AETSA) Avda. InnovaciĆ³n, s/n Edificio Arena 1. Sevilla (Spain) Tel. +34 955 006 309
Contact Name: aetsa.csalud@juntadeandalucia.es
Contact Email: aetsa.csalud@juntadeandalucia.es
Copyright: Andalusian Agency for Health Technology Assessment (AETSA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.